Immune thrombocytopenic purpura therapy (Oddifact)

N/A

Report date: 2025/05/16 16:52:15

Base Information

Drug NameImmune thrombocytopenic purpura therapy (Oddifact)
Drug Alias NameRituximab (Oddifact)利妥昔单抗 (Oddifact)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsPurpura, Thrombocytopenic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOddifact SAS
China Registration ClassN/A

Develop Information

Active CompaniesOddifact SAS
Inactive CompaniesN/A
Active IndicationsPurpura, Thrombocytopenic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A